NeuroSearch dives on further Huntexil woes
This article was originally published in Scrip
Executive Summary
Shares in the Danish biopharmaceutical firm NeuroSearch have plunged after the company said more clinical data would be required on its Huntington's disease drug, Huntexil (pridopidine), before it can file a new drug application, following preliminary feedback from US FDA after an end of Phase II meeting.